Rock Creek Pharmaceuticals to Present at the 2016 BIO International Convention and the LD Micro Invitational Conference

Jun 1, 2016

SARASOTA, Fla., June 1, 2016 /PRNewswire/ -- Rock Creek Pharmaceuticals, Inc., (OTCQB: RCPI), a clinical-stage drug development company focused on the application of its lead compound to treat acute and chronic inflammatory conditions, announced today that Michael Mullan, MBBS, Ph.D., Chairman and CEO of Rock Creek Pharmaceuticals, will be presenting the Company's ongoing drug development initiatives, as well as updates to the Company's corporate and regulatory strategy at two upcoming industry and investor conferences.

Rock Creek Pharmaceuticals

Dr. Mullan will first present at the 2016 BIO International Convention on Monday, June 6, 2016 at 3:30PM Pacific Time, in Room 2, at the Moscone Center in San Francisco, California. A live audio/slide webcast will be available on the Company's website and at the following link:

Dr. Mullan will also present at the 6th Annual LD Micro Invitational investor conference on June 9, 2016 at 10AM Pacific Time at the Luxe Sunset Bel Air Hotel in Los Angeles, California.  The LD Micro Invitational will feature 195 companies in the small/micro-cap space.

Both conferences will provide a venue to meet with investors, partnering prospects and biotechnology industry participants.

About Rock Creek Pharmaceuticals, Inc.:

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases.

For more information, visit:

About 2016 BIO International Convention:

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

For more information visit:

About LD Micro Invitational:

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

For those interested in attending, please contact David Scher at or visit for more information.

Forward Looking Statements:
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, failure to obtain sufficient capital resources to fund our development program and operations, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our significant payables, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, pending litigation matters, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2015 filed on March 22, 2016. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.


Investor Contact:
PCG Advisory Group
Stephanie Prince

Media Contact:
PCG Advisory Group
Sean Leous
646 863 8998

Company Contact:
Rock Creek Pharmaceuticals, Inc.
2040 Whitfield Ave. Suite 300
Sarasota Florida, 34243

Logo -

SOURCE Rock Creek Pharmaceuticals, Inc.

print email rss